NRXS Stock Analysis: Buy, Sell, or Hold?
NRXS - Neuraxis, Inc.
$6.15
-0.12 (-1.91%)
▼
5d:
-2.38%
30d:
-12.27%
90d:
-17.23%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When NRXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NRXS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NRXS shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: NRXS is currently trading at $6.15, which is considered oversold relative to its 30-day fair value range of $6.29 to $6.95.
Technical Outlook: Technically, NRXS is in a downtrend. Immediate support is located at $5.50, while resistance sits at $7.21.
Market Sentiment: NRXS scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $11.00 (+78.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NRXS is in a downtrend. Immediate support is located at $5.50, while resistance sits at $7.21.
Market Sentiment: NRXS scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $11.00 (+78.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.29 -
$6.95
Company Quality Score
45/100
(HOLD)
Options IV Signal
100th percentile
(ELEVATED)
Volume Confirmation
HIGH
Confidence Score
45.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 100th percentile)
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 78.9% below Wall St target ($11.00)
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$6.29 -
$6.95
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.16
(18.9%)
Support & Resistance Levels
Support Level
$5.50
Resistance Level
$7.21
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-22.78
Wall Street Target
$11.00
(+78.9%)
Revenue Growth (YoY)
115.7%
Profit Margin
-144.4%
Share & Embed Analysis
Last updated: August 22, 2026 6:25 PM ET
Data refreshes hourly during market hours. Next update: 7:25 PM
Data refreshes hourly during market hours. Next update: 7:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NRXS showing a specific setup today?
Insider Activity (6 Months)
3
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Brian Allen Carrico
BUY
8060 shares
2026-04-01
Thomas Joeseph Carrico
BUY
667 shares
2026-04-01
Timothy Robert Henrichs
BUY
7593 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$125 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 37 SELL |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$101 | 50 HOLD |
